AB-22 

AB-22, a vinyl sulfate compound, is an orally active antifungal agent. AB-22 inhibits hyphal growth and biofilm initiation by inhibiting the gene expression of ALS3, HWP1, and ECE1 in Candida albicans SC5314 cells. AB-22 can be used for the research of infrction, such as systemic candidiasis^[1].

AB-22 (4 μg/mL; 30-120 mins) delays germ tube formation of SC5314 cells^[1].
AB-22 (0.25-3 h) inhibits hyphal growth and biofilm initiation by inhibiting the gene expression of ALS3, HWP1, and ECE1 in SC5314 cells^[1].
AB-22 (0.5-4 μg/mL; 24 hours) inhibits hyphal growth of SC5314 cells^[1].
AB-22 (1-4 μg/mL; 24 hours) inhibits biofilm formation of SC5314 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

AB-22 (20-30 mg/kg, twice a day for 5 days or 300 mg/kg, a single dose; p.o.) improves survival in ICR mice infected with ATCC90028 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

475.97

C₂₂H₃₀ClN₇O₃

1463913-43-0

O=C(NN(CCO)C1=CC(C(C)C)=C(C(C)=NN2C)C2=N1)NC3=CC(OCCC)=NC(Cl)=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lee KT, et al. The novel antifungal agent AB-22 displays in vitro activity against hyphal growth and biofilm formation in Candida albicans and potency for treating systemic candidiasis. J Microbiol. 2022;60(4):438-443.  [Content Brief]